This Phase 2/3 clinical trial is conducted by Exciva targeting Alzheimer's disease[1]. The trial represents Exciva's advancement of a novel therapeutic candidate for Alzheimer's disease treatment, currently recruiting 300 participants in a randomized, placebo-controlled design[2].
Alzheimer's disease is the most common cause of dementia, affecting over 55 million people worldwide[3]. The disease is characterized by progressive cognitive decline, with underlying neuropathological hallmarks including amyloid-beta plaques and neurofibrillary tau tangles[4].
| Parameter | Value |
|---|---|
| Trial ID | NCT07284472 |
| Phase | Phase 2/3 |
| Status | Recruiting |
| Participants | 300 |
| Sponsor | Exciva |
| Indication | Alzheimer's Disease |
| Study Type | Interventional |
| Allocation | Randomized |
| Intervention Model | Parallel |
| Masking | Double-blind |
Exciva is a biotechnology company focused on developing innovative therapies for neurological disorders, with a particular emphasis on Alzheimer's disease and related dementias[2:1]. The company's approach includes:
The Alzheimer's disease treatment landscape has evolved significantly[5]:
| Drug | Target | Company | Approval Year |
|---|---|---|---|
| Aducanumab | Amyloid-beta plaques | Biogen | 2021 (accelerated) |
| Lecanemab | Protofibrils | Eisai/Biogen | 2023 |
| Donanemab | N-terminal pyroglutamate Aβ | Eli Lilly | 2024 |
The Alzheimer's disease drug development pipeline includes:
Despite recent approvals, several challenges remain[6]:
The trial employs a rigorous randomized, placebo-controlled, double-blind design[7]:
Active Treatment Arm(s)
Placebo Control Arm
| Phase | Duration |
|---|---|
| Screening | 4-8 weeks |
| Treatment Period | 52-78 weeks |
| Follow-up | 12-26 weeks |
| Total | 18-24 months |
Alzheimer's Disease Diagnosis
Amyloid Confirmation
Cognitive Requirements
Stability Requirements
Neurological Conditions
Psychiatric Conditions
Medical Conditions
Medication Contraindications
ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive)
CDR (Clinical Dementia Rating)
MMSE (Mini-Mental State Examination)
ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living)
CDR-SB (CDR Sum of Boxes)
The Exciva trial follows the anti-amyloid therapeutic approach that has shown clinical benefit in recent trials[10]:
Approved in 2023 based on CLARITY-AD trial[11]:
Approved in 2024 based on TRAILBLAZER-ALZ 2[12]:
From previous anti-amyloid trials[13]:
Patient Selection Matters
Amyloid Reduction Correlates with Benefit
Safety Management Critical
This trial contributes to several key research questions:
Novel Mechanism Validation
Biomarker Correlation
Combination Therapy Foundation
If successful, this trial could lead to:
The trial provides:
| Trial | Drug | Company | Primary Outcome | Status |
|---|---|---|---|---|
| CLARITY-AD | Lecanemab | Eisai/Biogen | CDR-SB | Approved |
| TRAILBLAZER-ALZ 2 | Donanemab | Eli Lilly | iADRS | Approved |
| NCT07284472 | Exciva candidate | Exciva | TBD | Recruiting |
| GRADUATE 1&2 | Gantenerumab | Roche | CDR-SB | Completed |
Alzheimer's disease drug development pipeline 2024. Alzheimer's & Dementia. 2024. ↩︎ ↩︎
Exciva Therapeutics. 2024. ↩︎ ↩︎
Alzheimer's disease: global consensus on therapeutic approaches. Lancet. 2021. ↩︎
Amyloid-beta and tau in Alzheimer's disease: a problematic paradigm. Nature Reviews Drug Discovery. 2019. ↩︎
Alzheimer's disease drug development pipeline 2022. Alzheimer's & Dementia. 2022. ↩︎
Antibody drugs for Alzheimer's disease face uncertain future. Nature Reviews Drug Discovery. 2023. ↩︎
Clinical trials in early Alzheimer's disease. Current Neurology and Neuroscience Reports. 2022. ↩︎
NIA-AA research framework: towards a biological definition of Alzheimer's disease. Alzheimer's & Dementia. 2018. ↩︎
Blood biomarkers for Alzheimer's disease. Nature Reviews Neurology. 2023. ↩︎
Anti-amyloid therapies for Alzheimer's disease. Nature Reviews Neurology. 2023. ↩︎
Lecanemab in early Alzheimer's disease. The New England Journal of Medicine. 2023. ↩︎
Donanemab in early Alzheimer's disease. The New England Journal of Medicine. 2021. ↩︎
Lecanemab: a milestone in Alzheimer's disease treatment. Journal of Prevention of Alzheimer's Disease. 2023. ↩︎